Risk assessment, screening and prevention of breast cancer: A look at cost-effectiveness

Breast

Volumn 19, Issue 4, 2010, Pages 260-267

  Lebovic, Gail S ^a   Hollingsworth, Alan ^b   Feig, Stephen A ^c  

^a American Society of Breast Disease   (United States)

^b Mercy Health Center   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Cost effectiveness; Mammography; Prevention; Risk assessment; Screening

Indexed keywords

RALOXIFENE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE QUALITY; HUMAN; MAMMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED STATES; BREAST NEOPLASMS; COST BENEFIT ANALYSIS; ECONOMICS; EPIDEMIOLOGY; FEMALE; HEALTH SERVICE; MASS SCREENING; PHYSICAL EXAMINATION; PRIMARY PREVENTION; PROCEDURES; RISK FACTOR; STATISTICS AND NUMERICAL DATA; WOMEN'S HEALTH;

BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MAMMOGRAPHY; MASS SCREENING; PHYSICAL EXAMINATION; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; UNITED STATES; WOMEN'S HEALTH; WOMEN'S HEALTH SERVICES;

EID: 77955338193     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2010.03.013     Document Type: Article

References (34)

1. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998, 90:1371-1388.
2. Hollingsworth A.B., Singletary S.E., Morrow M., Francescatti D.S., O'Shaughnessy J.A., Hartman A.-R., et al. Current comprehensive assessment and management of women at increased risk for breast cancer. Am J Surg 2004, 187:349-362.
3. Dooley W.C., Ljung B.M., Veronesi U., Cazzaniga M., Elledge R.M., O'Shaughnessy J.A., et al. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst 2001, 93:1624-1632.
4. Fabian C.J., Kimler B.F., Zalles C.M., Klemp J.R., Kamel S., Zeiger S., Mayo M.S. Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst 2000, 92:1217-1227.
5. Buehring G.C., Letscher A., McGirr K.M., Khandhar S., Che L.H., Nguyen C.T., Hackett A.J. Presence of epithelial cells in nipple aspirate fluid is associated with subsequent breast cancer: a 25-year prospective study. Breast Cancer Res Treat 2006, 98:63-70.
6. Baltzell K.A., Moghadassi M., Rice T., Sison J.D., Wrensch M. Epithelial cells in nipple aspirate fluid and subsequent breast cancer risk: a historic prospective study. BMC Cancer 2008, 8:75.
7. Wrensch M.R., Petrakis N.L., King E.B., Miike R., Mason L., Chew K.L., et al. Breast cancer incidence in women with abnormal cytology in nipple aspirates of breast fluid. Am J Epidemiol 1992, 135:130-141.
8. Vogel V.G., Costantino J.P., Wickerham D.L., Cronin W.M., Cecchini R.S., Atkins J.N., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes. JAMA 2006, 295:2727-2741.
9. Saslow D., Boetes C., Burke W., Harms S., Leach M.O., Lehman C.D., et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007, 57:75-89.
10. Taneja C., Edelsberg J., Weycker D., Guo A., Oster G., Weinreb J. Cost effectiveness of breast cancer screening with contrast-enhanced MRI in high-risk women. J Am Coll Radiol 2009, 6:171-179.
11. Rosenquist C.J., Lindfors K.K. Screening mammography in women aged 40-49 years: analysis of cost-effectiveness. Radiology 1994, 191:647-650.
12. Salzmann P., Kerlikowske K., Phillips K. Cost-effectiveness of screening mammography of women aged 40-49 years of age. Ann Intern Med 1997, 127:955-965.
13. Moskowitz M., Fox S.H. Cost analysis of aggressive breast cancer screening. Radiology 1979, 130:253-256.
14. Moskowitz M. Costs of screening for breast cancer. Radiol Clin North Am 1987, 25:1031-1037.
15. Eddy D.M. Screening for breast cancer. Ann Intern Med 1989, 111:389-399.
16. Feig S.A. Mammographic screening of women aged 40-49 years: benefit, risk, and cost considerations. Cancer 1995, 76:2097-2106.
17. Tabar L., Yen M.-F., Vitak B., Chen H.-H., Smith R.A., Duffy S.W. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 2003, 361:1405-1410.
18. Coldman A., Phillips N., Warren L., Kan L. Breast cancer mortality after screening mammography in British Columbia women. Int J Cancer 2007 Mar, 120(5):1076-1108.
19. Gold M., Siegel J., Russell L., Weinstein M. Cost-effectiveness in health and medicine 1996, Oxford University Press, New York.
20. Rosenquist C.J., Lindfors K.K. Screening mammography beginning at age 40 years: a reappraisal of cost-effectiveness. Cancer 1998, 82:2235-2240.
21. Tengs T.O., Adams M.E., Pliskin J.S., Safran D.G., Siegel J.E., Weinstein M.C., et al. Five hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995, 15:369-390.
22. Brown M.L. Sensitivity analysis in the cost-effectiveness of breast cancer screening. Cancer 1992, 69:1963-1967.
23. Van der Maas P.J., de Koning H.J., van Ineveld B.M., van Oortmarssen G.J., Habbema J.D., Lubbe K.T., et al. The cost-effectiveness of breast cancer screening. Int J Cancer 1989, 43:1055-1060.
24. Feig S.A. Increased benefit from shorter screening mammography intervals for women ages 40-49 years. Cancer 1997, 80:2035-2039.
25. Blanks R.G., Bennett R.L., Patrick J., Cush S., Davison C., Moss S.M. The effect of changing from one to two views at incident (subsequent) screens in the NHS breast-screening programme in England: impact on cancer detection and recall rates. Clin Radiol 2005, 60:674-680.
26. Pisano E.D., Gatsonis C., Hendrick E., Yaffe M., Baum J.K., Acharyya S., et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 2005, 353:1773-1783.
27. Tosteson A.N., Stout N.K., Fryback D.G., Acharyya S., Herman B.A., Hannah L.G., et al. Cost-effectiveness of digital mammography in breast cancer screening. Ann Intern Med 2008, 148:1-10.
28. Cyrlak D. Induced costs of low-cost screening mammography. Radiology 1988, 168:661-663.
29. Poplack S.P., Carney P.A., Weiss J.E., Titus-Ernstoff L., Goodrich M.E., Tosteson A.N., et al. Screening mammography: costs and use of screening-related services. Radiology 2005, 234:79-85.
30. Lidbrink E., Elfving J., Frisell J., Jonsson E. Neglected aspects of false positive findings of mammography in breast cancer screening: analysis of false positive cases from the Stockholm trial. BMJ 1996, 312:273-276.
31. Elmore J.G., Barton M.B., Moceri V.M., Polk S., Arena P.J., Fletcher S.W., et al. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 1998, 338:1089-1109.
32. Cuzick J., Forbes J.F., Sestak I., Cawthorn S., Hamed H., Holli K., et al. Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007, 99:272-282.
33. Powles T.J., Ashley S., Tidy A., Smith I.E., Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007, 99:283-290.
34. Cummings S.R., Tice J.A., Bauer S., Browner W.S., Cuzick J., Ziv E., et al. Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst 2009, 101:384-398.